Drug Profile


Alternative Names: HM 71224; LY 3337641

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Eli Lilly; Hanmi Pharmaceutical
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 17 Apr 2017 Chemical structure information added
  • 04 Apr 2017 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Singapore (PO) (NCT03099148)
  • 15 Mar 2017 Eli Lilly initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03083561)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top